Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International Database
- 1 June 2006
- journal article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (6), 2047-2054
- https://doi.org/10.1210/jc.2005-2284
Abstract
Treatment with GH has been used to correct the growth deficit in children with GH deficiency (GHD). Although successful in increasing height velocity, such treatment often falls short of helping patients achieve full genetic height potential. This study set out to analyze near-final height (FH) data from a cohort of GH-treated children with idiopathic GHD. Of 1258 evaluable patients in the Pfizer International Growth Database (KIGS) with GHD, 980 were of Caucasian origin, and 278 were of Japanese origin; 747 had isolated GHD (IGHD), and 511 had multiple pituitary hormone deficiencies (MPHD). Near-FH, relation to midparental height, and factors predictive of growth outcomes were the main outcome measures. Median height sd scores (SDS) at the start of treatment were -2.4 (IGHD) and -2.9 (MPHD) for Caucasian males and -2.6 (IGHD) and -3.4 (MPHD) for females, respectively; comparable starting heights were -2.9 (IGHD) and -3.6 (MPHD) for Japanese males and -3.3 (IGHD) and -4.0 (MPHD) for females, respectively. Corresponding near-adult height SDS after GH treatment were -0.8 (IGHD) and -0.7 (MPHD) for Caucasian males and -1.0 (IGHD) and -1.1 (MPHD) for females, respectively; and -1.6 (IGHD) and -1.9 (MPHD) for Japanese males and -2.1 (IGHD) and -1.8 (MPHD) for females, respectively. Differences between near-adult height and midparental height ranged between -0.6 and +0.2 SDS for the various groups, with the closest approximation to MPH occurring in Japanese males with MPHD. The first-year increase in height SDS and prepubertal height gain was highly correlated with total height gain, confirming the importance of treatment before pubertal onset. It is possible to achieve FH within the midparental height range in patients with idiopathic GHD treated from an early age with GH, but absolute height outcomes remain in the lower part of the normal range. Patients with MPHD generally had a slightly better long-term height outcome.Keywords
This publication has 18 references indexed in Scilit:
- Insulin-Like Growth Factor Binding Protein-3 Generation as a Measure of GH SensitivityJournal of Clinical Endocrinology & Metabolism, 2002
- Validated Multivariate Models Predicting the Growth Response to GH Treatment in Individual Short Children with a Broad Range in GH Secretion CapacitiesPediatric Research, 2000
- Final height in idiopathic growth hormone deficiency: the KIGS experienceActa Paediatrica, 1999
- Factors Determining Pubertal Growth and Final Height in Growth Hormone Treatment of Idiopathic Growth Hormone DeficiencyHormone Research, 1997
- Spontaneous Growth and Response to Growth Hormone Treatment in Children with Growth Hormone Deficiency and Idiopathic Short StaturePediatric Research, 1996
- Catch-up growth in early treated patients with growth hormone deficiency. Dutch Growth Hormone Working Group.Archives of Disease in Childhood, 1995
- Final Height in Children with Growth Hormone DeficiencyHormone Research, 1995
- Final Height in Children with Growth Hormone DeficiencyHormone Research, 1995
- Standard Growth Charts for Height and Weight of Japanese Children from Birth to 17 Years Based on a Cross-sectional Survey of National DataClinical Pediatric Endocrinology, 1993
- Secular acceleration of growth in height in Japanese and its social backgroundAnnals of Human Biology, 1982